ストックスクリーナーアプリを入手
55.83
3.00%
1.625
アフターアワーズ：
55.20
-0.63
-1.13%
Spruce Biosciences Inc (SPRB) 最新ニュース
SPRB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Spruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval Pathway - Finviz
SPRB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Spruce Biosciences to Present at Upcoming Investor Conferences in March - Investing News Network
Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Rating of "Hold" by Analysts - MarketBeat
Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference - MarketBeat
Spruce Biosciences Inc. (SPRB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Total debt per share of Spruce Biosciences, Inc. – NASDAQ:SPRB - TradingView
Carlyle Group Inc. Expands Stake in Spruce Biosciences Inc. - GuruFocus
Millennium group (SPR B) joint Schedule 13G shows ~103K shares (~9.6%) - Stock Titan
HC Wainwright Has Positive Outlook for SPRB FY2025 Earnings - MarketBeat
SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy - Stocktwits
Regulatory De-Risking and Extended Runway Underpin Maintained Buy Rating on Spruce Biosciences - TipRanks
SPRB Analyst Rating Update: HC Wainwright Lowers Price Target | - GuruFocus
Carlyle Group Inc. Takes Position in Spruce Biosciences, Inc. $SPRB - MarketBeat
Spruce Biosciences Stock Falls 5% Despite Positive Outcomes From Two Recent Type B Meetings With FDA - Nasdaq
Spruce Biosciences Gains After Positive FDA Type B Meetings On TA-ERT - Nasdaq
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
Spruce Biosciences, Inc. shares recorded a significant increase, rising by 8.16% in a single day. - Bitget
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Investing News Network
Biotech working on neurological drugs joins Oppenheimer stage - Stock Titan
Spruce Biosciences recently announced that its candidate drug TA-ERT for Sanfilippo syndrome type B (also known as MPS IIIB) received positive feedback during a Type B meeting with the U.S. Food and Drug Administration (FDA). - Bitget
SPRB PE Ratio & Valuation, Is SPRB Overvalued - Intellectia AI
SPRB Should I Buy - Intellectia AI
Spruce Biosciences: TA-ERT’s Promising Long-Term Data and Priority Review Voucher Upside Underpin Reiterated Buy and $220 Target - TipRanks
Experimental enzyme therapy stabilizes skills for 6 years in fatal disorder - Stock Titan
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team - BioSpace
Spruce Biosciences Makes Two SVP Appointments - Contract Pharma
Spruce Biosciences (NASDAQ:SPRB) Shares Up 0.6%Time to Buy? - MarketBeat
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™ - BioSpace
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium - Investing News Network
Harbour BioMed Exercises Warrant to Acquire 3.8% of Spruce Biosciences Inc. - intellectia.ai
Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences - Benzinga
Harbour BioMed Acquires Stake in U.S. Partner Spruce Biosciences, Signaling Strategic Shift in Chinese Biotech - IndexBox
Harbour BioMed Acquires 3.8% of Spruce Biosciences, Enhancing Strategic Partnership - Intellectia AI
Harbour BioMed Expands Stake in Spruce Biosciences (SPRB) - GuruFocus
Harbour BioMed Exercises Agreement to Buy Spruce Biosciences Common Stock - Contract Pharma
Harbour BioMed Acquires 3.8% Stake in Spruce Biosciences - Intellectia AI
Harbour BioMed Acquires 3.8% Stake in Spruce Biosciences (SPRB) - Intellectia AI
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deep - GuruFocus
Harbour BioMed Exercises Warrant To Acquire Stake In Spruce Biosciences - Nasdaq
HBM Holdings Deepens Ties With Spruce Biosciences via Warrant Exercise - TipRanks
Harbour BioMed buys into Spruce to back new hormone disorder drug - Stock Titan
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration - Barchart.com
Harbour BioMed takes stake in Spruce Biosciences - MSN
Spruce Biosciences (SPRB) Price Target Increased by 10.02% to 235.11 - Nasdaq
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital - BioSpace
Spruce Biosciences secures up to $50 million in growth capital from Avenue Capital - marketscreener.com
Spruce Biosciences Signs Multiple Financing Agreements - TradingView — Track All Markets
5.71%
0.02%
大文字化:
|
ボリューム (24 時間):